Answers are grounded in this paper and cite their sources.
JAK2 V617F, CALR and MPL mutations are treated as mutually exclusive in essential thrombocythaemia (ET), and testing usually stops once JAK2 V617F is found. Coexisting mutations cluster at a low JAK2 allele burden, but whether they define a distinct phenotype in Chinese patients is unresolved. We compared 24 Chinese patients with coexisting JAK2 V617F and CALR mutations, nine of them identified from published reports, with 110 patients with isolated JAK2 V617F and 21 with an isolated CALR mutation, and analysed phenotype, allele burdens, revised IPSET-thrombosis categories, treatment and transformation with permutation testing, Holm-Bonferroni correction and competing-risk analysis. Co-mutated patients had higher haemoglobin (12 g/L, 95% confidence interval 3–23) and more splenomegaly (55.0% versus 24.3%), both borderline after correction (adjusted P = .051 and .054), together with a lower JAK2 V617F burden (22.4% versus 27.0%; below 5% in 3 of 13 versus 3 of 65). Two thirds (66.7%) were classified as high risk because the revised International Prognostic Score of thrombosis counts JAK2 positivity alone. Thrombotic risk could not be assessed, since a thrombosis field was recorded for only six CALR-mutated controls. Transformation was more frequent in co-mutated patients in both analyses (12.5% and 20.0% versus 3.6%), but the significance was not stable (P = .111 and .038). Coexisting mutations therefore mark a phenotype that leans towards JAK2-mutated ET without a confirmed excess of thrombotic or transformative risk, and CALR exon 9 should be tested whenever JAK2 V617F is present.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: